170 related articles for article (PubMed ID: 19637333)
1. Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers.
Joeres-Nguyen-Xuan TH; Boehm SK; Joeres L; Schulze J; Kruis W
Inflamm Bowel Dis; 2010 Feb; 16(2):256-62. PubMed ID: 19637333
[TBL] [Abstract][Full Text] [Related]
2. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.
Henker J; Müller S; Laass MW; Schreiner A; Schulze J
Z Gastroenterol; 2008 Sep; 46(9):874-5. PubMed ID: 18810672
[TBL] [Abstract][Full Text] [Related]
3. Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial.
Petersen AM; Mirsepasi H; Halkjær SI; Mortensen EM; Nordgaard-Lassen I; Krogfelt KA
J Crohns Colitis; 2014 Nov; 8(11):1498-505. PubMed ID: 24972748
[TBL] [Abstract][Full Text] [Related]
4. Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
Scaldaferri F; Gerardi V; Mangiola F; Lopetuso LR; Pizzoferrato M; Petito V; Papa A; Stojanovic J; Poscia A; Cammarota G; Gasbarrini A
World J Gastroenterol; 2016 Jun; 22(24):5505-11. PubMed ID: 27350728
[TBL] [Abstract][Full Text] [Related]
5. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
Kruis W; Fric P; Pokrotnieks J; Lukás M; Fixa B; Kascák M; Kamm MA; Weismueller J; Beglinger C; Stolte M; Wolff C; Schulze J
Gut; 2004 Nov; 53(11):1617-23. PubMed ID: 15479682
[TBL] [Abstract][Full Text] [Related]
6. Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis.
Losurdo G; Iannone A; Contaldo A; Ierardi E; Di Leo A; Principi M
J Gastrointestin Liver Dis; 2015 Dec; 24(4):499-505. PubMed ID: 26697577
[TBL] [Abstract][Full Text] [Related]
7. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
Adam B; Liebregts T; Holtmann G
Z Gastroenterol; 2006 Mar; 44(3):267-9. PubMed ID: 16514573
[No Abstract] [Full Text] [Related]
8. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial.
Stollman N; Magowan S; Shanahan F; Quigley EM;
J Clin Gastroenterol; 2013 Aug; 47(7):621-9. PubMed ID: 23426454
[TBL] [Abstract][Full Text] [Related]
9. Morphometric analysis of the porcine gastrointestinal tract in a 10-day high-dose indomethacin administration with or without probiotic bacteria Escherichia coli Nissle 1917.
Bures J; Pejchal J; Kvetina J; Tichý A; Rejchrt S; Kunes M; Kopacova M
Hum Exp Toxicol; 2011 Dec; 30(12):1955-62. PubMed ID: 21441285
[TBL] [Abstract][Full Text] [Related]
10. Absorption kinetics of 5-aminosalicylic acid in rat: influence of indomethacin-induced gastrointestinal lesions and Escherichia Coli Nissle 1917 medication.
Kunes M; Kvetina J; Kholova D; Bures J; Tlaskalova-Hogenova H; Pavlik M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():46-52. PubMed ID: 22167206
[TBL] [Abstract][Full Text] [Related]
11. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
Kruis W; Schütz E; Fric P; Fixa B; Judmaier G; Stolte M
Aliment Pharmacol Ther; 1997 Oct; 11(5):853-8. PubMed ID: 9354192
[TBL] [Abstract][Full Text] [Related]
12. Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis.
Park SK; Kang SB; Kim S; Kim TO; Cha JM; Im JP; Choi CH; Kim ES; Seo GS; Eun CS; Han DS; Park DI
Korean J Intern Med; 2022 Sep; 37(5):949-957. PubMed ID: 36068716
[TBL] [Abstract][Full Text] [Related]
13. [Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?].
Folwaczny C
Z Gastroenterol; 2000 Jun; 38(6):547-50. PubMed ID: 10923365
[No Abstract] [Full Text] [Related]
14. Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers.
Henker J; Laass MW; Blokhin BM; Maydannik VG; Bolbot YK; Elze M; Wolff C; Schreiner A; Schulze J
Pediatr Infect Dis J; 2008 Jun; 27(6):494-9. PubMed ID: 18469732
[TBL] [Abstract][Full Text] [Related]
15. Influence of E. coli strain Nissle 1917 (EcN) on intestinal gas dynamics and abdominal sensation.
Hernando-Harder AC; von Bünau R; Nadarajah M; Singer MV; Harder H
Dig Dis Sci; 2008 Feb; 53(2):443-50. PubMed ID: 17712634
[TBL] [Abstract][Full Text] [Related]
16. The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers.
Henker J; Laass M; Blokhin BM; Bolbot YK; Maydannik VG; Elze M; Wolff C; Schulze J
Eur J Pediatr; 2007 Apr; 166(4):311-8. PubMed ID: 17287932
[TBL] [Abstract][Full Text] [Related]
17. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad.
Faubion WA; Sandborn WJ
Gastroenterology; 2000 Mar; 118(3):630-1. PubMed ID: 10702217
[No Abstract] [Full Text] [Related]
18. The use of Escherichia coli strain Nissle 1917 shows promise for improving gastrointestinal and urinary health in dogs.
Rudinsky AJ; Harrison A; Shi B; Hardison R; Prinster T; Huang S; Lee S; Byron JK; Lucas E; Mason KM; Li H; Wolff C; von Buenau R; Bornack B; Justice SS
Am J Vet Res; 2023 Aug; 84(8):. PubMed ID: 37353214
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN).
Matthes H; Krummenerl T; Giensch M; Wolff C; Schulze J
BMC Complement Altern Med; 2010 Apr; 10():13. PubMed ID: 20398311
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Potential of
Oh GM; Moon W; Seo KI; Jung K; Kim JH; Kim SE; Park MI; Park SJ
Korean J Gastroenterol; 2021 Jan; 77(1):12-21. PubMed ID: 33361702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
